{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:42:20Z","timestamp":1756384940688},"reference-count":52,"publisher":"Infectious Disease and Control Branch (IDPCB) - Public Health Agency of Canada","issue":"ACS-1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.14745\/ccdr.v39i00a01","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T20:16:29Z","timestamp":1519848989000},"page":"1-40","source":"Crossref","is-referenced-by-count":3,"title":["UPDATE ON THE USE OF QUADRIVALENT CONJUGATE MENINGOCOCCAL VACCINES"],"prefix":"10.14745","volume":"39","author":[{"given":"This statement was prepared by Dr. B","family":"Warshawsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5795","published-online":{"date-parts":[[2013,1]]},"reference":[{"key":"key20180228151622_r1","first-page":"2","article-title":"An Advisory Committee Statement (ACS). Statement on recommended use of meningococcal vaccines","volume":"27","author":"National Advisory Committee on Immunisation (NACI)","year":"2001","journal-title":"Can Commun Dis Rep"},{"key":"key20180228151622_r2","first-page":"10","article-title":"Supplementary statement on conjugate meningococcal vaccines","volume":"29","author":"National Advisory Committee on Immunization (NACI)","year":"2003","journal-title":"Can Commun Dis Rep"},{"key":"key20180228151622_r3","first-page":"1","article-title":"Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135","volume":"33","author":"National Advisory Committee on Immunization (NACI)","year":"2007","journal-title":"Can Commun Dis Rep"},{"key":"key20180228151622_r4","first-page":"1","article-title":"Meningococcal C conjugate vaccination recommendations for infants. An Advisory Committee Statement (ACS)","volume":"33","author":"National Advisory Committee on Immunization (NACI)","year":"2007","journal-title":"Can Commun Dis Rep"},{"key":"key20180228151622_r5","first-page":"1","article-title":"An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS)","volume":"35","author":"National Advisory Committee on Immunization (NACI)","year":"2009","journal-title":"Can Commun Dis Rep"},{"issue":"3","key":"key20180228151622_r6","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/INF.0b013e31819040e7","article-title":"The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada","volume":"28","author":"Canadian Immunization Monitoring Program, Active (IMPACT)","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"key20180228151622_r7","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.vaccine.2009.01.026","article-title":"Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006","volume":"27","year":"2009","journal-title":"Vaccine"},{"issue":"5","key":"key20180228151622_r8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/BF03405245","article-title":"Impact of routine immunization using meningococcal C conjugate vaccine on invasive meningococcal disease in British Columbia","volume":"99","year":"2008","journal-title":"Can J Public Health"},{"key":"key20180228151622_r9"},{"key":"key20180228151622_r10","unstructured":"Public Health Agency of Canada. Publicly funded immunization programs in Canada \u2013 routine schedule for infants and children. www.phac-aspc.gc.ca\/im\/ptimprog-progimpt\/table-1-eng.php Accessed on June 23, 2011."},{"issue":"6","key":"key20180228151622_r11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/INF.0b013e31820a8b3c","article-title":"Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine","volume":"30","author":"Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"key20180228151622_r12"},{"issue":"3","key":"key20180228151622_r13","first-page":"72","article-title":"Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"key20180228151622_r14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1473-3099(04)01251-4","article-title":"Meningococcal polysaccharide-protein conjugate vaccines","volume":"5","year":"2005","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"key20180228151622_r15","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","year":"1969","journal-title":"J Exp Med"},{"issue":"17-18","key":"key20180228151622_r16","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection--serum bactericidal antibody activity","volume":"23","year":"2005","journal-title":"Vaccine"},{"issue":"6","key":"key20180228151622_r17","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/JCM.32.6.1475-1482.1994","article-title":"Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay","volume":"32","year":"1994","journal-title":"J Clin Microbiol"},{"issue":"7-8","key":"key20180228151622_r18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0264-410X(99)00276-5","article-title":"Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults","volume":"18","year":"1999","journal-title":"Vaccine"},{"issue":"9","key":"key20180228151622_r19","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1086\/344324","article-title":"Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom","volume":"186","year":"2002","journal-title":"J Infect Dis"},{"issue":"10","key":"key20180228151622_r20","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1128\/IAI.71.10.5549-5555.2003","article-title":"Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom","volume":"71","year":"2003","journal-title":"Infect Immun"},{"issue":"21","key":"key20180228151622_r21","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1001\/jama.283.21.2795","article-title":"Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial","volume":"283","year":"2000","journal-title":"JAMA"},{"issue":"6","key":"key20180228151622_r22","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1086\/314753","article-title":"Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory","volume":"179","year":"1999","journal-title":"J Infect Dis"},{"issue":"1","key":"key20180228151622_r23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/317646","article-title":"Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers","volume":"183","year":"2001","journal-title":"J Infect Dis"},{"key":"key20180228151622_r24"},{"issue":"2","key":"key20180228151622_r25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","article-title":"Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine","volume":"24","year":"2005","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"key20180228151622_r26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/00006454-200208000-00010","article-title":"Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children","volume":"21","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"key20180228151622_r27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.vaccine.2009.10.104","article-title":"Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age","volume":"28","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"key20180228151622_r28","first-page":"173","article-title":"Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial","volume":"299","year":"2008","journal-title":"JAMA"},{"issue":"5","key":"key20180228151622_r29","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"key20180228151622_r30"},{"issue":"3","key":"key20180228151622_r31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/INF.0b013e31818e037d","article-title":"Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants","volume":"28","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"key20180228151622_r32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10096-009-0848-8","article-title":"Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers","volume":"29","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key20180228151622_r33"},{"issue":"50","key":"key20180228151622_r34","doi-asserted-by":"crossref","first-page":"7865","DOI":"10.1016\/j.vaccine.2010.09.092","article-title":"Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age","volume":"28","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"key20180228151622_r35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/INF.0b013e31818a0237","article-title":"A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents","volume":"28","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"key20180228151622_r36","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1086\/599117","article-title":"Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents","volume":"49","author":"V59P13 Study Group","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"11","key":"key20180228151622_r37","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.6.11.12849","article-title":"Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo\u00ae) or Menactra\u00ae among healthy adolescents","volume":"6","year":"2010","journal-title":"Hum Vaccin"},{"issue":"12","key":"key20180228151622_r38","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1128\/CVI.00207-09","article-title":"Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra","volume":"16","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"key20180228151622_r39"},{"issue":"37","key":"key20180228151622_r40","first-page":"1042","article-title":"Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease","volume":"58","author":"Centers for Disease Control and Prevention (CDC)","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"18","key":"key20180228151622_r41","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/j.vaccine.2010.02.045","article-title":"Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines","volume":"28","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"key20180228151622_r42","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1128\/CVI.00436-09","article-title":"Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults","volume":"17","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"key20180228151622_r43","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1542\/peds.2009-2336","article-title":"Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel","volume":"125","author":"Protocol 025 Investigators","year":"2010","journal-title":"Pediatrics"},{"key":"key20180228151622_r44"},{"issue":"34","key":"key20180228151622_r45","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","article-title":"Glycoconjugate vaccines and immune interference: A review","volume":"28","year":"2010","journal-title":"Vaccine"},{"key":"key20180228151622_r46"},{"key":"key20180228151622_r47"},{"issue":"14","key":"key20180228151622_r48","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1016\/j.vaccine.2005.12.018","article-title":"Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine","volume":"24","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"key20180228151622_r49","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.inf.0000126297.28952.f8","article-title":"Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants","volume":"23","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"key20180228151622_r50","first-page":"1","article-title":"Guidelines for the prevention and control of meningococcal disease","volume":"31","author":"Public Health Agency of Canada","year":"2005","journal-title":"Can Commun Dis Rep"},{"key":"key20180228151622_r51"},{"issue":"3","key":"key20180228151622_r52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0749-3797(01)00261-6","article-title":"Current methods of the US Preventive Services Task Force: a review of the process","volume":"20","author":"Methods Work Group, Third US Preventive Services Task Force","year":"2001","journal-title":"Am J Prev Med"}],"container-title":["Canada Communicable Disease Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/migration\/phac-aspc\/publicat\/ccdr-rmtc\/13vol39\/acs-dcc-1\/assets\/pdf\/acs-dcc-4-eng.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T21:16:21Z","timestamp":1603919781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/migration\/phac-aspc\/publicat\/ccdr-rmtc\/13vol39\/acs-dcc-1\/assets\/pdf\/acs-dcc-4-eng.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":52,"journal-issue":{"issue":"ACS-1","published-online":{"date-parts":[[2013,1]]},"published-print":{"date-parts":[[2013,1]]}},"URL":"https:\/\/doi.org\/10.14745\/ccdr.v39i00a01","relation":{},"ISSN":["1481-8531"],"issn-type":[{"value":"1481-8531","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}